HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

At its annual FDA Cosmetic Regulatory Workshop, ICMAD encourages members to support new cosmetics safety legislation launched Apr. 18 by Rep. Leonard Lance, R-N.J. Additionally, RIFM adds a new president, Dr. David K. Wilcox, and FDA names Walter Harris COO.

You may also be interested in...



Industry Vets Launch Boutique Fragrance Firm; Miss Universe Is First Client

The Miss Universe Organization is first to sign a licensing agreement with fragrance marketer and distributor Omni Scents, founded by former Parlux Fragrances CEO Neil Katz. Firm looks forward to launching three scents under the deal in August, noting that approximately 1 billion people in 190 countries tuned in to the 2012 Miss Universe pageant.

Parlux Rolls Out First Celeb Scents Since Perfumania Merger

New fragrances from Paris Hilton and Jessica Simpson are the first to emerge from Parlux since Bellport, N.Y.-based Perfumania completed its $118 million acquisition of the firm in April.

Industry-Backed Cosmetics Bill Will “Not Be Easy To Pass” – Rep. Lance

At a May 7 press conference held at L’Oreal USA’s Research and Innovation Center, Rep. Leonard Lance, R-N.J., admitted having “a lot of work to do” to convince colleagues that the Safe Cosmetics Alliance-backed Cosmetic Safety Amendments Act “is the way forward.”

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel